This study assessed compared photon and proton treatment techniques, such as intensity modulated radiation therapy (IMRT), uniform scanning proton therapy (USPT), and intensity modulated proton therapy (IMPT), for a total of 10 prostate cancers. All treatment plans delivered 70 Gy to 95% of the planned target volume in 28 fractions. IMRT plans had 7 fields for the step and shoot technique, while USPT and IMPT plans employed two equally weighted, parallel-opposed lateral fields to deliver the prescribed dose to the planned target. Inverse planning was then incorporated to optimize IMPT. The homogeneity index (HI) and conformity index (CI) for the target and the normal tissue complication probability (NTCP) for organ at risk (OAR) were calculated. Although the mean HI and CI for target were not significantly different for each treatment techniques, the NTCP of the rectum was 2.233, 3.326, and 1.707 for IMRT, USPT, and IMPT, respectively. The NTCP of the bladder was 0.008, 0.003, and 0.002 respectively. The NTCP values at the rectum and bladder were significantly lower using IMPT. Our study shows that using proton therapy, particularly IMPT, to treat prostate cancer could be beneficial compared to 7-field IMRT with similar target coverage. Given these results, radiotherapy using protons, particularly optimized IMPT, is a worthwhile treatment option for prostate cancer.
INTRODUCTION
Internationally, prostate cancer rates have increased annually.
In 2008, prostate cancer rates were the highest of all cancer rates in the US and UK, fourth in Japan, and fifth in Korea. 1) In recent years, the number of cancer patients treated with external beam radiotherapy has increased. The goal of radiotherapy is to deliver a prescription dose to a tumor while minimizing the dose to surrounding normal tissues and organs at risk (OAR). Conformal radiation techniques, including stereotactic patient positioning, multi-leaf collimation, and intensity modulated radiotherapy (IMRT), allow significantly improved dose distributions.
2) IMRT can produce complex dose distributions and is capable of delivering a radical radiotherapy dose to the prostate while reducing the volumes of the small and the large bowel irradiated to significant doses. 3) With a proton beam the dose is largely deposited in the Bragg peak at the end of the particle's range, with no dose delivered beyond a few millimeters past the peak. Therefore, proton beams are a great tool to spare healthy tissue around the target. 4 
MATERIALS AND METHODS

Treatment simulation and volume definition
We selected 10 localized prostate cancer patients. Table 1 shows the characteristics of the 10 patients. All patients under- (Fig. 1a ).
Uniform scanning proton treatment planning
Proton therapy treatment plans were created for prostate cancer patients using a RayStation V 2.4 treatment planning system (RaySearch Laboratories, Stockholm, Sweden) for IBA Proteus 235 machine and dose kernels are calculated using the pencil beam dose algorithm of the treatment planning system which takes heterogeneities into account also within the cross sections of the spots. The USPT plan stacks uniform fluence energy layers combined with a PMMA compensator. The USPT plan employed two equally weighted, parallel-opposed lateral fields to deliver the prescribed dose to the PTV. We used relatively small margins in planning because various uncertainties had already been included in the PTV. Fig. 1b shows the actual treatment plan for Patient 2, using bilateral beams, and the corresponding coronal and axial views with the dose distribution.
Intensity modulated proton treatment planning
The IMPT plan also employed two lateral beams using a RayStation planning system. Each beam was initially generated such that it delivered a flat SOBP to the target volume. To explore improvements to proton therapy treatment, individual pencil beams were not of equal weight. Initially, weighting the individual pencil beams equally led to a gradient SOBP, which gave higher doses proximal to the target than a flat SOBP. 13) Inverse planning was then used to optimize the plan. Dose objectives were prescribed where 95% of the PTV volume received the prescription dose. After the PTV objectives had been achieved, the doses to the rectum, bladder, femoral heads, and the external contour were minimized as much as possible without compromising conformity in the PTV. The optimization constraints shown Table 2 were also used for IMPT planning. Fig. 1c show the actual IMPT plan, using bilateral beams, and the corresponding coronal and axial views with the dose distribution.
Analysis and evaluation
The DVH for the IMRT, USPT, and IMPT plans were compared for the PTV and for OAR, such as the rectum, bladder, and both femoral heads. We evaluated the Homogeneity Index (HI), defined as the ratio of the dose received by 5% of the PTV volume to that received by 95% of the PTV.
HI = D5 / D95
Where D5 and D95 are the doses received by 5% and 95%
of the PTV volume, respectively. Conformity of high dose around the target was evaluated by calculating the Conformity index (CI). The CI was defined as the ratio between the target volume (TV) and the reference isodose (VRI) volume. 14) CI = TV / VRI
The normal tissue complication probability (NTCP) was calculated for the rectum and bladder using the NTCP model proposed by Lyman, Kutcher, and Burman.
15)
RESULTS
PTV
All DVH curves in Fig. 2a slightly. The highest dose was 78.5 Gy for the 7-field step and shoot IMRT plan. The mean dose within the PTV was 72.0
Gy. USPT achieved a dose distribution in the PTV closest to the objectives, with a mean dose of 72.6 Gy and a maximum dose of 76 Gy. IMPT had a maximum dose of 71.6 Gy and a mean dose of 73.6 Gy ( Table 3 ). The CIs and HIs for PTV are given in Table 3 . The target dose conformity was determined by comparing the PTV volume with the volume encompassed by the 95% isodose body. The mean CIs were 1.14, 1.31, and 1.19 for IMRT, USPT, and IMPT, respectively.
The IMRT dose distributions were more conformal to the target. The mean HIs for IMRT, USPT, and IMPT were 1.06, 1.06, and 1.04, respectively.
Rectum and bladder
The principal objective of these plans was to attain similar PTV coverage, which could increase high dose rectal exposure.
The average DVH for the rectums of all 10 patients is shown in Fig. 2b . The IMPT plan was the most proficient in sparing the rectum. For doses less than 34 Gy, USPT gave lower dose to the target than IMRT. For doses more than 34 Gy, however, USPT delivered the higher dose. The mean doses for IMPT, USPT, and IMRT were 23.7 Gy, 32.5 Gy, and 36.1
Gy, respectively. at the rectum and bladder were lowest for IMPT.
Femoral heads
IMRT delivered the lowest dose to the right and left femoral heads comparing USPT and IMPT (Fig. 2d) . Also, IMRT delivered a mean dose to the femoral heads of 13.4 Gy and a maximum dose of 42.7 Gy. The highest mean exposure was due to USPT (27.5 Gy). Using a variety of angles between the IMRT beams meant no beam passed directly through the femoral heads, unlike the proton plans. Despite the lower mean dose of IMPT (18.9 Gy) compared to USPT (27.5 Gy), the maximum dose of IMPT in the femoral heads was approximately 10 Gy higher for USPT. USPT gave higher levels of low dose exposure principally due to the beam arrangement.
Despite this, USPT at doses above 30 Gy exposes the smallest volumes.
DISCUSSION
Several randomized prostate cancer trials have shown that higher doses are associated with significantly improved biochemical control. [16] [17] [18] High radiation doses, however, are lim-ited by the risk of chronic rectal and bladder toxicity. 19, 20) Proton therapy has been proposed to deliver elevated doses with potentially lower toxicity to normal surrounding struc-
tures. Yet, few reports have compared the dosimetric qualities. 4, 21) Vergas compared dose-volume between proton therapy using double scattering and IMRT for prostate cancer. 21) This study involved examining treatment plans generated for 10 prostate cancer patients. The IMRT plans generated by Vargas used 5
fields. With these plans PT gave a better whole dose than IMRT in the PTV and achieved values closer to the prescribed dose. In contrast to our results, the rectal DVH curve for PT was significantly lower than the IMRT curve for all doses ＞ 80 Gy. 
CONCLUSION
Our study shows that using proton therapy, particularly IMPT, to treat prostate cancer could be beneficial compared to 7-field IMRT and USPT. Homogeneity in the PTV is better using IMPT. Optimized proton therapy also gave better sparing of the bladder, rectum, and femoral heads, although rectal sparing was similar to IMRT and USPT at high doses. Improved protons techniques have the potential to greatly reduce the dose delivered to healthy tissue, possibly reducing second malignancies. Given these results, radiotherapy using protons, particularly IMPT, represents a worthwhile treatment option for prostate cancer.
